Pear Therapeutics receives FDA breakthrough device designation for prescription digital therapeutic candidate to treat alcohol use disorder

Pear Therapeutics

22 November 2021 – Pear Therapeutics today announced that it has received breakthrough device designation from the U.S. FDA for its reSET-A PDT product candidate designed for the treatment of alcohol use disorder.

reSET-A potentially expands Pear’s addiction franchise, which includes FDA authorised products to treat substance use disorder and opioid use disorder.

Read Pear Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder